logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics says chief operating officer, chief medical officer and president of R&D, Dr David Roblin to leave from 31 January

Chief executive officer Glyn Edwards said: “David has been instrumental in establishing our leadership position in new mechanism antibiotic development"

Boardroom
The news comes a day after Summit revealed that American authorities have increased their financial backing of a programme developing a next-generation antibiotic.

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) announced that its chief operating officer, chief medical officer and president of R&D, Dr David Roblin has resigned from the company with effect from 31 January 2020.

In a brief statement, Summit’s chief executive officer Glyn Edwards said: “David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our Phase 3 clinical trials of ridinilazole for the treatment of C. difficile infection.”

READ: Summit Therapeutics receives further US$8.8mln boost to antibiotic programme

“We are grateful to David for building a strong team that will continue to advance Summit’s important work and wish him all the very best in his future endeavours,” Edwards added.

The news comes a day after Summit revealed that American authorities have increased their financial backing of a programme developing a next-generation antibiotic.

The Biomedical Advanced Research and Development Authority (BARDA) is pumping a further US$8.8mln into the advancement of Summit’s precision drug ridinilazole for the treatment of C. difficile infection (CDI) taking the total value of the award to US$72.5mln.

The latest US cash injection will support a new clinical trial in adolescent patients, which in turn is expected to help with the new drug application for ridinilazole.

Quick facts: Summit Therapeutics PLC

Price: 20.5 GBX

AIM:SUMM
Market: AIM
Market Cap: £68.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

2 weeks, 5 days ago

2 min read